Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, approval, Europe | Leave a Comment »
Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, approval, Europe, Zytiga | Leave a Comment »
The European Medicines Agency (EMA) has announced the launch of the EU Clinical Trials Register. This trial register will allow residents of the 27 EU member states, as well as Iceland, Liechtenstein, and Norway, to more easily find data about clinical trials of therapies for the management of prostate cancer (including new drugs).
Filed under: Uncategorized | Tagged: clinical trials, Europe, register | Leave a Comment »
According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana)
Filed under: Drugs in development, Management, Treatment | Tagged: approval, cabazitaxel, EMEA, Europe, Jevtana | Leave a Comment »
The European Association of Urology (EAU) has issued updated guidelines on the screening, diagnosis, and treatment of clinically localized prostate cancer.
Filed under: Diagnosis, Management, Treatment | Tagged: Europe, guideline, localized | 6 Comments »
The gold standard treatment for clinical stage T3 prostate cancer has long been the combination of radiotherapy and extended hormone therapy. However, the accuracy of clinical staging based on DRE is open to some question, since 20 percent of patients assessed to have cT3 prostate cancer today appear to be over-staged during physical examination.
Filed under: Management, Treatment | Tagged: cT3 disease, Europe, surgical treatment | Leave a Comment »
The three reports in today’s news cover: A future perspective on treatments for localized disease Robot-assisted laparoscopic prostatectomy in Europe Long-term follow-up on urinary toxicities following brachytherapy
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, cryoablation, Europe, HIFU, phoptodynamic therapy, RALP, urinary toxicity | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site